American Thoracic Society - Sanofi Investor Call

BOREAS Clinical Trial Design (NCT03930732) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab Administered Every 2 Weeks in Patients with Moderate or Severe COPD with Type 2 Inflammation Week-4 Week 52 Week 64 Follow-up Baseline Screening Randomization N=939 Treatment Period Dupilumab SC 300 mg q2w N=468 203 Placebo SC q2w N=471 ATS 2023 20 20

View entire presentation